C Lueck1, G McIlwaine. 1. Department of Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh, Scotland, UK, EH4 2XU. cl@skull.dcn.ed.ac.uk
Abstract
BACKGROUND: Idiopathic intracranial hypertension (IIH) occurs throughout the world with an estimated incidence of one to three per 100,000 population per year. It occurs most commonly in obese young women, but the cause is unknown. It presents a significant threat to sight and is associated with severe morbidity in the form of headaches in the majority of cases. Several different treatments have been proposed, ranging from relatively conservative measures such as diuretic therapy to more invasive treatments such as optic nerve sheath fenestration or lumbo-peritoneal shunting. OBJECTIVES: The aim of this review is to assess the evidence from controlled trials looking at the various treatments used for idiopathic intracranial hypertension with a view to producing an evidence-based treatment strategy. SEARCH STRATEGY: We searched the Cochrane Controlled Trials Register - CENTRAL/CCTR (which contains the Cochrane Eyes and Vision Group specialised register) on the Cochrane Library Issue 2, 2002, MEDLINE (1966 to March 2002) and EMBASE (1980 to February 2002). SELECTION CRITERIA: We included only randomised controlled trials in which any intervention used to treat idiopathic intracranial hypertension had been compared to placebo or to another form of treatment in people with a clinical diagnosis of idiopathic intracranial hypertension. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed the search results for trials to be included in the review. Discrepancies were resolved by discussion. Since no trials met our inclusion criteria, no assessment of quality or meta-analysis was undertaken. MAIN RESULTS: No randomised controlled trials were found that met the inclusion criteria. REVIEWER'S CONCLUSIONS: There is insufficient information to generate an evidence-based management strategy for idiopathic intracranial hypertension. Of the various treatments available, there is inadequate information regarding which are truly beneficial and which are potentially harmful. Properly designed and executed trials are needed.
BACKGROUND:Idiopathic intracranial hypertension (IIH) occurs throughout the world with an estimated incidence of one to three per 100,000 population per year. It occurs most commonly in obese young women, but the cause is unknown. It presents a significant threat to sight and is associated with severe morbidity in the form of headaches in the majority of cases. Several different treatments have been proposed, ranging from relatively conservative measures such as diuretic therapy to more invasive treatments such as optic nerve sheath fenestration or lumbo-peritoneal shunting. OBJECTIVES: The aim of this review is to assess the evidence from controlled trials looking at the various treatments used for idiopathic intracranial hypertension with a view to producing an evidence-based treatment strategy. SEARCH STRATEGY: We searched the Cochrane Controlled Trials Register - CENTRAL/CCTR (which contains the Cochrane Eyes and Vision Group specialised register) on the Cochrane Library Issue 2, 2002, MEDLINE (1966 to March 2002) and EMBASE (1980 to February 2002). SELECTION CRITERIA: We included only randomised controlled trials in which any intervention used to treat idiopathic intracranial hypertension had been compared to placebo or to another form of treatment in people with a clinical diagnosis of idiopathic intracranial hypertension. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed the search results for trials to be included in the review. Discrepancies were resolved by discussion. Since no trials met our inclusion criteria, no assessment of quality or meta-analysis was undertaken. MAIN RESULTS: No randomised controlled trials were found that met the inclusion criteria. REVIEWER'S CONCLUSIONS: There is insufficient information to generate an evidence-based management strategy for idiopathic intracranial hypertension. Of the various treatments available, there is inadequate information regarding which are truly beneficial and which are potentially harmful. Properly designed and executed trials are needed.
Authors: Zi Yang Jiang; Caitlin McLean; Carlos Perez; Samuel Barnett; Deborah Friedman; Bobby A Tajudeen; Pete S Batra Journal: J Neurol Surg B Skull Base Date: 2017-09-04
Authors: Rory J Piper; Aristotelis V Kalyvas; Adam M H Young; Mark A Hughes; Aimun A B Jamjoom; Ioannis P Fouyas Journal: Cochrane Database Syst Rev Date: 2015-08-07
Authors: Afroditi-Despina Lalou; Marek Czosnyka; Zofia H Czosnyka; Deepa Krishnakumar; John D Pickard; Nick J Higgins Journal: Acta Neurochir (Wien) Date: 2019-12-12 Impact factor: 2.216